Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology & Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HDAC6 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HDAC6 Full-Length & Catalytic Domain Proteins (Active). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View HDAC6 Products |
| Gene Delivery | HDAC6 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction (HEK293T, HeLa). | View HDAC6 Products |
| Benchmark Ab | Anti-HDAC6 Control Antibody (High-Affinity Research Clone). Recombinant positive control for western blot and ELISA. | View HDAC6 Products |
| Validator | HDAC6 siRNA Set (3 pre-designed sequences). For knockdown verification and specificity controls. | View HDAC6 Products |
| Related Target: HDAC1 | Critical for selectivity counter-screening (nuclear toxicity avoidance). Class I comparator. | View HDAC1 Products |
| Related Target: HDAC10 | Class IIb homolog for subfamily specificity testing in selective inhibitor design. | View HDAC10 Products |
| Related Target: TUBA1A | Downstream substrate (α-tubulin) for functional activity assays. | View TUBA1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Class I Isoform Selectivity (vs HDAC1/2/3) | HDAC1/HDAC2/HDAC3 isoform panel available with >95% purity for parallel counter-screening. |
| Dual Catalytic Domain Engagement | Full-length HDAC6 (1–1215 aa) and individual CD1/CD2 truncations strictly sequence-verified for bivalent binding studies. |
| CNS Penetration Modeling | High-concentration protein stability (>5 mg/mL) for biophysical assays mimicking CNS exposure. |
| Resistance Mutation Screening | Mutant variants (catalytic domain) available for acquired resistance mechanism studies. |
| False Positive Control | Validated siRNA included for specificity checks and target deconvolution. |
Live HDAC6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HDAC6-selective therapeutics is intensifying, with major players shifting focus from pan-HDAC inhibition to isoform-selective strategies that spare Class I activity. Because HDAC6 resides primarily in the cytoplasm and regulates microtubule dynamics and misfolded protein clearance, selective targeting avoids the severe hematological toxicities associated with Class I (nuclear) HDAC inhibition. As first-generation selective therapies like Ricolinostat advance in multiple myeloma combinations, the next wave of R&D is targeting neurodegenerative conditions (Charcot-Marie-Tooth, ALS, frontotemporal dementia) and immunological disorders through PROTAC-mediated degradation. The critical differentiator remains the therapeutic index—achieving potent α-tubulin deacetylase inhibition while avoiding thrombocytopenia and cardiac toxicity linked to HDAC1/2 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule | Celgene/BMS (Ricolinostat), Italfarmaco, Aurobindo | Multiple Myeloma, Lymphoma | Dual-Domain Inhibition Assay (Need full-length HDAC6 with native Zn-binding) |
| PROTAC Degrader | Arvinas, C4 Therapeutics, Academic Labs | Solid Tumors, Neurodegeneration | Cell-Based Degradation Assay (Need HDAC6 Lentivirus for stable reporter lines) |
| CNS-Penetrant Inhibitor | Acetylon (Krocuinostat), Biogen | ALS, Frontotemporal Dementia | Selectivity Panel (Need HDAC1/HDAC10 proteins for off-target screening) |
| Bispecific Domain Binder | Curis, Forma Therapeutics | Refractory Hematologic Malignancies | Domain-Specific Binding Assay (Need separate CD1 and CD2 truncations) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors:
- Selectivity Against Class I – Must achieve >1000-fold IC50 separation over HDAC1/2/3 to avoid platelet and cardiac toxicity. Pan-family counter-screening with HDAC1–3 proteins is essential.
- Dual Catalytic Domain Engagement – HDAC6 has two catalytic domains (CD1 and CD2). Full-length vs. truncated domain inhibition profiles reveal bivalent binding mechanism.
- Cellular Target Engagement – Measure Acetyl-α-tubulin levels by Western blot or high-content imaging using HDAC6-overexpressing stable cell lines built with TarMart lentivirus.
- PROTAC Ternary Complex Formation – Requires highly pure full-length HDAC6 for SPR/biophysical binding studies with E3 ligase.
- Resistance Mutation Profiling – Anticipate mutations like Tyr781; mutant proteins available for next-generation compound screening.
TarMart Solution Highlights: Isoform panels (HDAC1–11), full-length & truncated HDAC6, pre-made lentivirus, validated siRNA and control antibodies—all sequence-verified and >95% pure.
Related Targets for Cross-Selling
- HDAC1 / HDAC2 / HDAC3 – Essential for selectivity toxicity counter-screening.
- HDAC10 – Class IIb homolog for subfamily specificity.
- TUBA1A (α-Tubulin) – Primary HDAC6 substrate for functional verification.
- HSP90 – Another HDAC6 substrate and chaperone; relevant for aggregosome pathway studies.